Agricultural Biotech
Cancer / Genetics
Safe Pregnancy
Critical Habitat
Assessing Risk

About CETOS
Mission
Join Us
Donate
Search
Home

 

ASA Response

June 25, 1999

We are writing in regard to the article, "Experts take Biotech Critic to Task over Soybean Study," By Robert Steyer. The American Soybean Association (ASA) is going to lengths to make sure the soybean retains its  status as a miracle food.  The soybean has been making headlines because it contains estrogen-like substances (phytoestrogens) thought to protect against breast cancer, osteoporosis, and heart disease.  Of particular concern to our organization is that the soybean is being genetically altered to contain genes it otherwise would never contain, allowing the bean to withstand the overspray of Roundup® herbicide.  The beans we researched were Monsanto  isogenically  matched Roundup Ready™  varieties.

We thought it important for an independent organization to test Monsanto genetically altered soybeans for a few reasons.  First of all, the studies submitted to the Food and Drug Administration (FDA) for demonstrating the safety of genetically altered, Roundup Ready soybeans were conducted by Monsanto scientists and by direct association could lead to a conflict of interest.  Secondly, we discovered that the tests they conducted on phytoestrogen levels were on unsprayed soybeans. In other words, the genetically engineered beans were not those typically found on  supermarket shelves.  The point of engineering soybeans to resist Roundup® is that they are then typically sprayed at least twice in a growing season with high doses of Roundup®.  As an organization critiquing the conversion and introduction of bioengineered byproducts into our food system, we found it ethically important to independently study and test the sprayed Roundup Ready varieties.

The results of our peer-reviewed research, "Alterations in Clinically Important Phytoestrogens in Genetically Modified Herbicide-Tolerant Soybeans", to be published in the Journal of Medicinal Foods (Vol. 1, No. 4, in press), discuss our finding a significant reduction in phytoestrogen levels of 12-14% in the genetically altered soybean strains.  Significant sample to sample variability in two key biologically active components, genistin and daidzin, was evident in the two genetically altered Roundup Ready soybeans while the conventional varieties did not display as wide a variation.

While we shared our data months ago with Monsanto, its scientists prepared a paper for a potential simultaneous publication date and did not choose to share their data.  Monsanto s study to be published in the Journal of Agricultural and Food Chemistry (in press) claims the levels of isoflavones treated with glyphosate are "comparable to the parental soybean cultivar, and other conventional soybeans."  We understand Monsanto found widely  varying levels of isoflavones. We are also cognizant of the possibility that Monsanto s scientists used methods of extraction  which could be outdated.  We understand that older methods of isoflavone extraction have been replaced by newer methods which militate against the substantial variation found in previous studies.  To our understanding, the soybeanís phytoestrogens used in our research were extracted using newer methods.

The American Soybean Associationís website discussing our study quotes many leading experts including Dr. Clare Hasler and  Dr. Don Bullock. The experts state the levels of variationare well within the limits expected between soybean varieties.  Dr. Hasler says, "isoflavone amounts in soybeans can vary as much as 300 percent or more."  Dr. Bullock adds that soybeans vary in levels of phytoestrogens because of environmental factors, "such as weather during the growing season and even the slope of the field where the soybeans are grown".  But the soybeans we tested were marketed as identical with the exception of an additional gene enabling it to resist Roundup®.  The soybean varieties used in our research were grown in similar soil temperatures and climates.

While our independent tests found the same varying levels of phytoestrogens Monsanto scientists and other experts have been finding for years, we also discovered the ASA and others have been touting a soy products which according to them contain significantly unstable levels of plant estrogens. This point in and of itself warrants intensive investigation and research to assure consumers do not receive products with widely varying levels of phytoestrogens   We are further concerned that the ASA and others find it perfectly suitable to push the Food and Drug Administration to allow the addition of health claims on  soy products asserting  protections against life threatening diseases while having full knowledge of the varying phytoestrogen levels present in soy and its products.

We have always believed in the transparency of our work and were disappointed Monsanto scientists did not share their results with us.  We believe the  work we have conducted is an "initial" study and we would like to do more testing.  Unfortunately, we are no longer privy to obtaining Monsantoís seeds.  We were directly told by a Hartz seed company (a wholly owned subsidiary of Monsanto) representative who graciously supplied us with seed for our initial study, that he was told he could no longer provide us with seed samples. Even if we were to obtain seeds the chances of finding isogenically matched varieties is becoming increasingly more difficult.  When we contacted Hartz a few months ago, we were told there were 23 varieties of Roundup Ready™ soybeans and only 8 varieties of conventional.  Even if we wanted to move beyond our 2 variety- triplicate testing, we would not be able to expand our research beyond the levels of seed available.

The FDA has allowed the commercialization of Roundup Ready™ soybeans under the assumption that genetically altered soybeans were not significantly different than conventional counterparts. We found significant differences.  At a minimum there should be disclosures of the origins and isoflavone composition of soy products, as well as further independent research to establish expected baselines of phytoestrogens in transgenic and conventional soy products and byproducts.

Instead of recognizing the critical importance of uncovering the basis of this extraordinary variability in the soybean, the ASA has apparently gone to extreme lengths to challenge our findings.

Sincerely,
Dr. Marc Lappé &Ms. Britt Bailey